These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 17517836)

  • 21. Reference Susceptibility Testing and Genomic Surveillance of Clostridioides difficile, United States, 2012-17.
    Gargis AS; Karlsson M; Paulick AL; Anderson KF; Adamczyk M; Vlachos N; Kent AG; McAllister G; McKay SL; Halpin AL; Albrecht V; Campbell D; Korhonen LC; Elkins CA; Rasheed JK; Guh AY; McDonald LC; Lutgring JD;
    Clin Infect Dis; 2023 Mar; 76(5):890-896. PubMed ID: 36208202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of Binary Toxin Gene Detection and Decreased Susceptibility to Antibiotics among Clostridioides difficile Strains on Disease Severity: a Single-Center Study.
    Costa DVS; Pham NVS; Hays RA; Bolick DT; Goldbeck SM; Poulter MD; Hoang SC; Shin JH; Wu M; Warren CA
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0048922. PubMed ID: 35861541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Epidemiological study of Clostridium difficile strains isolated in Jean-Verdier-René-Muret hospitals from 2001 to 2007].
    Poilane I; Fantinato C; Cruaud P; Collignon A
    Pathol Biol (Paris); 2008; 56(7-8):412-6. PubMed ID: 18842360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Whole-Genome Sequencing Reveals the High Nosocomial Transmission and Antimicrobial Resistance of Clostridioides difficile in a Single Center in China, a Four-Year Retrospective Study.
    Wen X; Shen C; Xia J; Zhong LL; Wu Z; Ahmed MAEE; Long N; Ma F; Zhang G; Wu W; Luo J; Xia Y; Dai M; Zhang L; Liao K; Feng S; Chen C; Chen Y; Luo W; Tian GB
    Microbiol Spectr; 2022 Feb; 10(1):e0132221. PubMed ID: 35019676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimicrobial susceptibility of Clostridium difficile isolates in Israel.
    Tkhawkho L; Nitzan O; Pastukh N; Brodsky D; Jackson K; Peretz A
    J Glob Antimicrob Resist; 2017 Sep; 10():161-164. PubMed ID: 28729205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A nationwide study of molecular epidemiology and antimicrobial susceptibility of Clostridioides difficile in South Korea.
    Byun JH; Kim H; Kim JL; Kim D; Jeong SH; Shin JH; Kim YA; Shin JH; Shin KS; Uh Y
    Anaerobe; 2019 Dec; 60():102106. PubMed ID: 31655214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada.
    Bourgault AM; Lamothe F; Loo VG; Poirier L;
    Antimicrob Agents Chemother; 2006 Oct; 50(10):3473-5. PubMed ID: 17005836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo activities of nitazoxanide against Clostridium difficile.
    McVay CS; Rolfe RD
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2254-8. PubMed ID: 10952564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.
    Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN
    Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin.
    Snydman DR; McDermott LA; Jacobus NV; Thorpe C; Stone S; Jenkins SG; Goldstein EJ; Patel R; Forbes BA; Mirrett S; Johnson S; Gerding DN
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6437-43. PubMed ID: 26239985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimicrobial resistance progression in the United Kingdom: A temporal comparison of Clostridioides difficile antimicrobial susceptibilities.
    Jon J V; Mark H W; Jane F
    Anaerobe; 2021 Aug; 70():102385. PubMed ID: 34048922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fidaxomicin inhibits spore production in Clostridium difficile.
    Babakhani F; Bouillaut L; Gomez A; Sears P; Nguyen L; Sonenshein AL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S162-9. PubMed ID: 22752866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence, enumeration, and antimicrobial agent resistance of Clostridium difficile in cattle at harvest in the United States.
    Rodriguez-Palacios A; Koohmaraie M; LeJeune JT
    J Food Prot; 2011 Oct; 74(10):1618-24. PubMed ID: 22004807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.
    Shah D; Dang MD; Hasbun R; Koo HL; Jiang ZD; DuPont HL; Garey KW
    Expert Rev Anti Infect Ther; 2010 May; 8(5):555-64. PubMed ID: 20455684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016.
    Thorpe CM; McDermott LA; Tran MK; Chang J; Jenkins SG; Goldstein EJC; Patel R; Forbes BA; Johnson S; Gerding DN; Snydman DR
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31085514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
    Citron DM; Merriam CV; Tyrrell KL; Warren YA; Fernandez H; Goldstein EJ
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2334-8. PubMed ID: 12821492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular Characterization of, and Antimicrobial Resistance in,
    Imwattana K; Putsathit P; Knight DR; Kiratisin P; Riley TV
    Microb Drug Resist; 2021 Nov; 27(11):1505-1512. PubMed ID: 33956520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin.
    O'Connor R; Baines SD; Freeman J; Wilcox MH
    J Antimicrob Chemother; 2008 Oct; 62(4):762-5. PubMed ID: 18606787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clostridium difficile isolates resistant to fluoroquinolones in Italy: emergence of PCR ribotype 018.
    Spigaglia P; Barbanti F; Dionisi AM; Mastrantonio P
    J Clin Microbiol; 2010 Aug; 48(8):2892-6. PubMed ID: 20554809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.
    Kumar M; Mathur T; Barman TK; Ramkumar G; Bhati A; Shukla G; Kalia V; Pandya M; Raj VS; Upadhyay DJ; Vaishnavi C; Chakrabarti A; Das B; Bhatnagar PK
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5986-9. PubMed ID: 22869573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.